Report Highlights
-
Apoptosis research is a new, booming field. Between the mid-1980's and the mid-1990's, the number of Medline citations containing the words "apoptosis" or "programmed cell death" increased by a factor of ten. This rapid growth has led to widespread availability of commercial kits and reagents for research use, and, more recently, to the formation of pharmaceutical companies devoted to developing apoptosis-modulating drugs. Although still growing at a fantastic rate, the kits and reagents market has become relatively established, while the pharmaceutical market is still in its infancy. Tremendous opportunities exist in both areas.
INTRODUCTION
STUDY GOALS AND OBJECTIVES
Apoptosis is a process through which cells initiate their own deaths. Also called cellular suicide and programmed cell death, apoptosis is vital to the development and survival of many organisms, because it allows an organism to rid itself of damaged or unnecessary cells. However, when genetic mutations or other problems alter apoptotic processes, diseases can result. For example, certain mutations can render cells unable to initiate apoptosis -- a condition that can lead to uncontrolled cellular proliferation and cancer. Alternatively, mutations that do not allow apoptosis to stop may play a role in the pathogenesis of Alzheimer's disease. Additionally, some viruses inactivate genes that control apoptosis, and force cells to remain alive and in service to viral reproduction.
This report discusses pharmaceutical and technological applications of apoptosis. This field promises to bring important new treatments for cancers, neurological conditions, cardiac problems, and other diseases. The report also addresses the state of the market for apoptosis-related research kits and reagents. It also analyzes the latest research on the subject, examines investments in drug development, and forecasts worldwide sales of drugs, kits, and reagents. Market forecasts project sales to the year 2005.
REASONS FOR DOING THE STUDY
Apoptosis research is a new, booming field. Between the mid-1980's and the mid-1990's, the number of Medline citations containing the words "apoptosis" or "programmed cell death" increased by a factor of ten. This rapid growth has led to widespread availability of commercial kits and reagents for research use, and, more recently, to the formation of pharmaceutical companies devoted to developing apoptosis-modulating drugs. Although still growing at a fantastic rate, the kits and reagents market has become relatively established, while the pharmaceutical market is still in its infancy. Tremendous opportunities exist in both areas.
Advances in molecular and cellular biology are fueling basic discoveries, while processes like combinatorial chemistry and new therapies such as antisense technology are fueling pharmaceutical discoveries. Current trends indicate that apoptosis-modulating drugs may eventually form a major therapeutic category, especially in the area of cancer therapy.
AUDIENCE FOR THE REPORT
Apoptosis-related drugs, kits, and reagents are a growing segment of the pharmaceutical and biotechnology industries. Considerable activity in both industries focuses on licensing and patenting technologies. Many licensing opportunities come from academic laboratories, although in-house development is also common.
This report discusses the structure of the industry, and provides profiles of major companies in each area. The report is directed at decision makers in each industry segment, as well as at individuals and organizations considering investing in apoptosis technology. These people include, but are not limited to the following:
- Venture capitalists
- Merger and acquisition executives
- Market and product management professionals
- Chief scientists and technical officers
- Equipment manufacturers
- Reagent suppliers
SCOPE AND FORMAT
This report is a tool whose purpose is to analyze the emerging industry in apoptosis-related products. The section following this introduction provides a summary of the report and its conclusions. An overview of the market and a brief discussion of relevant scientific principles follow the summary. The ensuing sections analyze current and future market trends. The final chapters address the structures of the apoptosis-related pharmaceutical and biotechnology industries. There is also an analysis of patents and their importance.
The appendices of the report contain directories of companies, associations, and conferences, as well as a list of research products and the companies selling them.
METHODOLOGY AND INFORMATION SOURCES
The material for this report was gathered from interviews with individuals in the industry, as well as a thorough review of technology gathered from secondary sources. These sources include company annual, 10K and 10Q reports, company literature, trade literature, trade associations, and online sources. Final projections are based on the analysis of information from primary and secondary sources. All dollar projections are presented in year 2000 constant dollars.
Related Reports
Recent Reports
Companion Diagnostics: Technologies and Markets
The global market for companion diagnostics is estimated to increase from $7.6 billion in 2023 to reach $15.4 billion by 2028, at a compound annual growth rate (CAGR) of 15.2% from 2023 through 2028.
Exosome Diagnostics, Therapeutics and Research Tools: Global Markets
The global market for exosome diagnostics, therapeutics and research tools is estimated to increase from $227.5 million in 2023 to reach $1.3 billion by 2028, at a compound annual growth rate (CAGR) of 42.2% from 2023 through 2028.
Peptide Synthesis: Global Markets
The global market for peptide synthesis is expected to grow from $90.1 billion in 2023 and projected to reach $157.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.8% during the forecast period of 2023 to 2028.
Oligonucleotides: Global Markets
The global market for oligonucleotides is expected to grow from $7.0 billion in 2023 and projected to reach $11.7 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2023 to 2028.
Global Market for Cell and Gene Therapy
The global market for cell and gene therapy is expected to grow from $7.2 billion in 2023 and projected to reach $23.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.4% during the forecast period of 2023 to 2028.
Top Trending Reports
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for cell and gene therapy tools and reagents is estimated to grow from $8.3 billion in 2022 to $13.7 billion in 2027, with a compound annual growth rate (CAGR) of 10.6% for the period of 2022-2027.
ESG Trends in Chemical Industry
This report focuses on the ESG trends in the chemical industry and evaluates the ESG implementation including current and future potential. The report utilizes various databases, including sustainability reports, annual reports, and other indicators used to develop the current market. The study provides detailed information on the main factors influencing ESG growth in the chemical industry. It enables the reader to understand the industry in general while also providing insight into the inter-relationship between ESG and the sustainable chemical industry. The report describes market growth, developing trends, industry leaders, and applications of ESG implementation in the chemical industry.
Digital Pathology: Technologies and Global Markets
The global digital pathology market is estimated to increase from $5.9 billion in 2022 to reach $10.7 billion by 2027, at a compound annual growth rate (CAGR) of 12.5% from 2022 through 2027.
Smartphone-Based Patient Monitoring: Global Market
The global smartphone-based patient monitoring market should reach $21.5 billion by 2027 from $6.8 billion in 2022 at a compound annual growth rate (CAGR) of 25.9% for the forecast period of 2022 to 2027.
Seawater and Brackish Water Desalination
The global market for seawater and brackish water desalination is estimated to increase from $14.7 billion in 2022 to $21.7 billion by 2027, at a compound annual growth rate (CAGR) of 8.1% from 2022 through 2027.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More